Report error Found 58 Enz. Inhib. hit(s) with all data for entry = 2705
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Streptococcus pyogenes serotype M3)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Streptococcus pyogenes serotype M3)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 28nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Streptococcus pyogenes serotype M3)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 34nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Streptococcus pyogenes serotype M3)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 50nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 56nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 62nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 96nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 110nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 160nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 160nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 220nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 240nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 250nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 270nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 290nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 330nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 410nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 410nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 470nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 570nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 790nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.10E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.20E+3nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.60E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.60E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.10E+3nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.10E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.20E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Haemophilus influenzae (strain ATCC 51907 / DSM 11...)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.40E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.70E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 3.20E+3nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 3.70E+3nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Staphylococcus aureus (strain NCTC 8325 / PS 47))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 3.80E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 3.80E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 4.40E+3nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 5.00E+3nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 6.00E+3nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 6.10E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 8.40E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Staphylococcus aureus (strain NCTC 8325 / PS 47))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.00E+4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.00E+4nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.01E+4nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.14E+4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Staphylococcus aureus (strain NCTC 8325 / PS 47))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.23E+4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Haemophilus influenzae (strain ATCC 51907 / DSM 11...)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.00E+4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.20E+4nMAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Staphylococcus aureus (strain NCTC 8325 / PS 47))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.40E+4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Enterococcus faecalis (strain ATCC 700802 / V583))
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.50E+4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
